These results suggest that, regardless of the microenvironmental synaptic changes in calcium ions that occur during AD, the two prime targets of those changes (CaN, CaMKII) appear to be viable choices as therapeutic targets. The gene discussed is NUP214; the disease is Alzheimer disease.